A review on Iguratimod: Bridging Hope for Arthritis Patients through the Dual Power of Immunomodulation and Anti-inflammation
Published: 2024-05-18
Page: 79-89
Issue: 2024 - Volume 7 [Issue 1]
Nikita Gupta
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana-510. India.
Sana Begum
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana-510. India.
Varda Farooqui
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana-510. India.
Summaiya Afreen
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana-510. India.
Pranitha Avunoori *
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana-510. India.
*Author to whom correspondence should be addressed.
Abstract
Iguratimod is a small novel compound considered as a disease-modifying anti-rheumatic drug (DMARD), which exhibits anti-inflammatory and immunomodulatory effects. Iguratimod acts directly on B cells by inhibiting the production of inflammatory cytokines (tumor necrosis factor-α, interleukin (IL)-1β, IL-6, IL-8, IL-17), thereby suppressing the production of immunoglobulin and inhibiting the activity of nuclear factor kappa-light chain enhancer of activated B cells. Preclinical studies demonstrate its positive impact on arthritis models in animals by reducing immunoglobulin production and various inflammatory cytokines. Iguratimod demonstrates its efficacy as well as tolerance when used as an additional therapy for rheumatoid arthritis patients who exhibit an insufficient response to both methotrexate and biological disease-modifying anti-rheumatic drugs. Additionally, iguratimod was found to possess an anabolic effect on bone metabolism, through both stimulations of osteoblastic differentiation and inhibition of osteoclastogenesis.
Further, the mechanism also involves suppressing nuclear factor kappa B (NF-κB) activation without blocking NF-κB inhibitor α (IκBα) degradation. Although the true target molecules of iguratimod have been unclear, it would be necessary to suppose the multiple mechanisms including suppression of NF-κB. Clinical trials of rheumatoid arthritis patients have shown more effectiveness and tolerability when compared to salazosulfapyridine, making iguratimod a promising DMARD with unique novel properties and positive clinical outcomes. Further research will determine its suitability as an alternative for patients unable to use biologics.
Keywords: Anti-inflammation, iguratimod, arthritis, immunomodulation
How to Cite
References
Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-11.
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: Update. Arthritis Rheum. 2002;46: 328-46
Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflammation Res. 2002;51(4):188–194. DOI:10.1007/PL00000291
Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatol. (Oxford). 2003;42(11):1365–1371. DOI: 10.1093/rheumatology/keg381
Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappab activation in cultured human synovial cells. J. Rheumatol. 2001;28(12):2591–2596.
Jiang Y, Lü W, Yu S, Yao L, Xu G, Zhang X. Inhibitory effect of iguratimod on TNFalpha production and NF-kappaB activity in LPS-stimulated rat alveolar macrophage cell line. Yao Xue Xue Bao. 2006;41(5):401–405.
Gan K, Yang L, Xu L, Feng X, Zhang Q, Wang F, et al. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. Int Immunopharmacol. 2016;35:294–300. DOI:10.1016/j.intimp.2016.03.038
Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C. Pharmacological studies of the new antiinflammatory agent 3- formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: Antiinflammatory, analgesic and other related properties. Arzncim.-Forsch./Drug Rcs. 1992;42(7):935–44.
Tanaka K, Makino S, Shimotori T, Aikawa Y, Inaba T, Yoshida C. Pharmacological studies of the new antiinflammatory agent 3- formylamino-7-methylsulfonylamino-6-phenoxy-4'-1-benzopyran-4-o ne. 2nd communication: Effect on the arachidonic acid cascades. Arzncim.-Forsch./Drug Rcs. 1992;42(7):945–50.Google Scholar
Tanaka K, Shimotori T, Makino S, Eguchi M, Asaoka K, Kitamura R, et al. Pharmacological studies on 3-formylamino-7-methylsulfonylamino6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 3rd communication: The involvement of bradykinin in its analgesic actions. J Pharmacobio-Dyn. 1992;15(11):641–7. DOI: 10.1248/bpb1978.15.641
Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: Inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobio-Dyn. 1992;15(11):649–55. DOI: 10.1248/bpb1978.15.649
Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol. 1995;67(4):305–14. DOI: 10.1254/jjp.67.305.59
Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatol (Oxford). 2003;42(11):1365–71. DOI: 10.1093/rheumatology/keg381
Morimoto K, Miura A, Tanaka K. Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain. Inflamm Res. 2017;66(10):855–62. DOI: 10.1007/s00011-017-1064-0
Jiang XP, Huang XL, Yang ZP, Wang SC, Xie W, Miao L, et al. Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis. Mol Immunol. 2018;93:9–19. DOI:10.1016/j.molimm.2017.10.008
Li G, Yamasaki R, Fang M, Masaki K, Ochi H, Matsushita T, et al. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Sci Rep. 2018;8(1):1933. DOI: 10.1038/s41598-018-20390-5
Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol. 2001;28(12):2591–6.
Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflammation Res. 2002;51 (4): 188–94. DOI:10.1007/pl00000291
Jiang H, Gao H, Wang Q, Wang M, Wu B. Molecular mechanisms and clinical application of Iguratimod: A review. BioMed Pharmacother. 2020;122: 109704. DOI:10.1016/j.biopha.2019.109704
Li B, Li P, Bi L. Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients. Clin Rheumatol. 2020;39(3):899–907. DOI:10.1007/s10067-019-04835-4
Yan Q, Du F, Huang X, Fu Q, Chen S, Dai D, et al. Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. Plos One. 2014;9(10):e108273. DOI:10.1371/journal.pone.0108273
Ye Y, Liu M, Tang L, Du F, Liu Y, Hao P, et al. Iguratimod represses b cell terminal differentiation linked with the inhibition of pkc/egr1 axis. Arthritis Res. Ther. 2019;21(1):92. DOI:10.1186/s13075-019-1874-2
Tanaka K, Yamamoto T, Taniguchi Y, Muramoto K. Inhibition of immunoglobulin production by T-614 (Iguratimod), a novel DMARD, in cultured B cells and in animal models of arthritis. Arthritis Rheum. 2004;50:S369.
Yamamoto T, Aikawa Y, Funaki J, et al. Immunopharmacological studies of a disease-modifying antirheumatic drug iguratimod (T-614); Its effect on immunogloblin production and lymphocyte proliferation. Jpn Pharmacol Ther. 2007; 35:561-9.
Muramoto K, Yamamoto T, Hishinuma I, Tanaka K. Pharmacological profile of a novel DMARD; T-614 (Iguratimod) on Ig production from B cells. In: Abstracts of the 2004 International Conference on B Cells and Autoimmunity; Quebec, Canada.
Tanaka K, Shimotori T, Taniguchi Y, et al. Pharmacological studies on T-614, a novel antiinflammatory agent: Effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/l mice. Int J Immunother. 1993;9:69-78.
Urata N, Yamamoto M, Taniguchi Y, et al. Effect of a disease-modifying antirheumatic drug iguratimod (T-614) on chronic arthritis in experimental animals. Jpn Pharmacol Ther. 2007;35:571-82.
De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002;46: 2029-33.
Yamamoto M, Urata N, Yamamoto T, et al. Effect of a disease-modifying antirheumatic drug iguratimod (T-614) on inflammatory cytokine production. Jpn Pharmacol Ther. 2007;35:551-9.
Jiang Y, Lü W, Yu SQ, et al. Inhibitory effect of iguratimod on TNFα production and NF-κB activity in LPS-stimulated rat alveolar macrophage cell line. Yao Xue Xue Bao. 2006;41:401-5.
Kohno M, Aikawa Y, Tsubouchi Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells. J Rheumatol. 2001;28:2591-6.
Kawakami A, Tsuboi M, Urayama S, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med. 1999;133:566-74.
Aikawa Y, Tanuma N, Shin T, et al. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol. 1998;89:35-42.
Tanaka K, Urata N, Mikami M, et al. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26- induced cachexia in mice. Inflamm Res. 2007;56:17-23.
Du F, Lü LJ, Fu Q, et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther. 2008;10:R136.
Ulsamer A, Ortuno MJ, Ruiz S, et al. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38, J. Biol. Chem. 2008;283(7):3816–3826.
Song J, Liu H, Zhu Q, et al., T-614 promotes osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-kappaB, Biomed Res. Int. 2018;(2018) 4901591.
Yamaguchi M, Arbiser JL, Weitzmann MN. Honokiol stimulates osteoblastogenesis by suppressing NF-kappaB activation, Int. J. Mol. Med. 2011;28(6):1049–1053.
Lacey DL, Timms E, Tan HL, et al., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell. 1998;93(2):165–176.
Wang XT, Li P, Xu TS, Ding R, Zhang X, Bi LQ. Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1beta-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis, Cell. Mol. Biol. (Noisy-le-grand). 2016;62(12):44–50.
Ren YH, Dong W, Liu H, Liu L. Clinical observation of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis, China Pharmacy. 2017;28(32):4530–4532.
Wu YX, Sun Y, Ye YP, et al., Iguratimod prevents ovariectomyinduced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator activated receptorgamma, Mol. Med. Rep. 2017;16(6):8200–8208.
Gan K, Yang L, Xu L, et al. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-kappaB and MAPK pathways, Int. Immunopharmacol. 2016; 35:294–300.
Du F, Lu LJ, Teng JL, Shen N, Ye P, Bao CD. T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, In vitro, Int. Immunopharmacol. 2012;13(1):54– 60.
Nam JL, Winthrop KL, Van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA, Ann. Rheum. Dis. 2010;69(6):976–986.
Wei Y, Sun X, Hua M, Tan W, Wang F, Zhang M, Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients, Biomed Res. Int. 2015;214683.